Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Incidence of Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-analysis, and Meta-regression.
Orci LA, Sanduzzi-Zamparelli M, Caballol B, Sapena V, Colucci N, Torres F, Bruix J, Reig M, Toso C. Orci LA, et al. Among authors: sapena v. Clin Gastroenterol Hepatol. 2022 Feb;20(2):283-292.e10. doi: 10.1016/j.cgh.2021.05.002. Epub 2021 May 28. Clin Gastroenterol Hepatol. 2022. PMID: 33965578 Free article. Review.
Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules.
Mariño Z, Darnell A, Lens S, Sapena V, Díaz A, Belmonte E, Perelló C, Calleja JL, Varela M, Rodriguez M, Rodriguez de Lope C, Llerena S, Torras X, Gallego A, Sala M, Morillas RM, Minguez B, Llaneras J, Coll S, Carrion JA, Iñarrairaegui M, Sangro B, Vilana R, Sole M, Ayuso C, Ríos J, Forns X, Bruix J, Reig M. Mariño Z, et al. Among authors: sapena v. J Hepatol. 2019 May;70(5):874-884. doi: 10.1016/j.jhep.2019.01.005. Epub 2019 Jan 24. J Hepatol. 2019. PMID: 30684506
Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib.
Díaz-González Á, Sanduzzi-Zamparelli M, Sapena V, Torres F, LLarch N, Iserte G, Forner A, da Fonseca L, Ríos J, Bruix J, Reig M. Díaz-González Á, et al. Among authors: sapena v. Aliment Pharmacol Ther. 2019 Mar;49(5):482-491. doi: 10.1111/apt.15088. Epub 2019 Jan 29. Aliment Pharmacol Ther. 2019. PMID: 30695819
Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis.
Sapena V, Enea M, Torres F, Celsa C, Rios J, Rizzo GEM, Nahon P, Mariño Z, Tateishi R, Minami T, Sangiovanni A, Forns X, Toyoda H, Brillanti S, Conti F, Degasperi E, Yu ML, Tsai PC, Jean K, El Kassas M, Shousha HI, Omar A, Zavaglia C, Nagata H, Nakagawa M, Asahina Y, Singal AG, Murphy C, Kohla M, Masetti C, Dufour JF, Merchante N, Cavalletto L, Chemello LL, Pol S, Crespo J, Calleja JL, Villani R, Serviddio G, Zanetto A, Shalaby S, Russo FP, Bielen R, Trevisani F, Cammà C, Bruix J, Cabibbo G, Reig M. Sapena V, et al. Gut. 2022 Mar;71(3):593-604. doi: 10.1136/gutjnl-2020-323663. Epub 2021 Mar 19. Gut. 2022. PMID: 33741640 Free article.
Pancreatic Insufficiency in Patients Under Sorafenib Treatment for Hepatocellular Carcinoma.
Díaz-González Á, Belmonte E, Sapena V, Sanduzzi-Zamparelli M, Darnell A, Díaz A, Gomes da Fonseca L, Llarch N, Iserte G, Ayuso C, Forner A, Feu F, Bruix J, Rimola J, Reig M. Díaz-González Á, et al. Among authors: sapena v. J Clin Gastroenterol. 2021 Mar 1;55(3):263-270. doi: 10.1097/MCG.0000000000001366. J Clin Gastroenterol. 2021. PMID: 32530871
Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules.
Sanduzzi-Zamparelli M, Mariño Z, Lens S, Sapena V, Iserte G, Pla A, Granel N, Bartres C, Llarch N, Vilana R, Nuñez I, Darnell A, Belmonte E, García-Criado A, Díaz A, Muñoz-Martinez S, Ayuso C, Bianchi L, Fuster-Anglada C, Rimola J, Forner A, Torres F, Bruix J, Forns X, Reig M. Sanduzzi-Zamparelli M, et al. Among authors: sapena v. J Hepatol. 2022 Apr;76(4):874-882. doi: 10.1016/j.jhep.2021.11.023. Epub 2021 Nov 29. J Hepatol. 2022. PMID: 34856322
Pharmacokinetics and pharmacogenetics of sorafenib in patients with hepatocellular carcinoma: Implications for combination trials.
Díaz-González Á, Sapena V, Boix L, Brunet M, Torres F, LLarch N, Samper E, Millán O, Corominas J, Iserte G, Sanduzzi-Zamparelli M, da Fonseca LG, Darnell A, Belmonte E, Forner A, Ayuso C, Bruix J, Reig M. Díaz-González Á, et al. Among authors: sapena v. Liver Int. 2020 Oct;40(10):2476-2488. doi: 10.1111/liv.14587. Epub 2020 Jul 25. Liver Int. 2020. PMID: 33021346
41 results